| Bioactivity | Sulazepam, a benzodiazepine, is a selective ovarian cancer G protein-coupled receptor (OGR1) agonist. Sulazepam has anticonvulsive action and has the potential for airway hyperresponsiveness (AHR) research[1][2]. |
| In Vivo | Sulazepam (3.2 mg/kg in 25 µL via intranasal route ∼30 min before HDM challenge; 5 days a week for three consecutive weeks) inhibits the development of airway hyperresponsiveness (AHR) in Male and female wild-type C57BL/6 mice (8-10 wk old), but not in age-matched OGR1KO mice (C57BL/6 background) with house dust mite (HDM) allergen (25 μg; intranasally)[1]. |
| Name | Sulazepam |
| CAS | 2898-13-7 |
| Formula | C16H13ClN2S |
| Molar Mass | 300.81 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Ajay P Nayak, et al. OGR1-dependent regulation of the allergen-induced asthma phenotype. Am J Physiol Lung Cell Mol Physiol. 2021 Dec 1;321(6):L1044-L1054. [2]. Tonio Pera, et al. Biased signaling of the proton-sensing receptor OGR1 by benzodiazepines. FASEB J. 2018 Feb;32(2):862-874. |